Genmab A/S Dkk (GNMSF) 182.0500 $GNMSF Genmab Enters

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genmab A/S Dkk (GNMSF) 182.0500 $GNMSF

Genmab Enters Commercial License Agreement with Gilead for DuoBody(R) Technology
GlobeNewswire - Wed Aug 10, 12:08PM CDT
Company Announcement
GEN: 2.00 (-0.01)

Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance
GlobeNewswire - Tue Aug 09, 10:11AM CDT
Interim Report for First Half 2016

Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:05AM CDT
Will drug stocks Mylan, Incyte and Genmab be able to pull a surprise when they report Q2 results on Aug 9?
JNJ: 123.22 (-0.55), INCY: 81.05 (-0.16), MYL: 48.46 (-0.25), NVS: 82.08 (-0.72)

Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 11:17AM CDT
Genmab (GNMSF) announced that CHMP issued a negative opinion for Arzerra as a maintenance therapy for relapsed chronic lymphatic leukemia.
JNJ: 123.22 (-0.55), ANIP: 69.58 (+0.48), NVS: 82.08 (-0.72)

Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL
GlobeNewswire - Thu Jun 23, 9:33AM CDT
-- Committee for Medicinal Products for Human Use (CHMP) issues negative opinion for Arzerra for maintenance treatment of patients with relapsed CLL
GEN: 2.00 (-0.01), NVS: 82.08 (-0.72)

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 51.98 (-0.09), JNJ: 123.22 (-0.55), PFE: 34.98 (-0.17), LGND: 113.94 (-0.77), BMY: 60.63 (-0.34), AMPH: 18.10 (-0.56)

Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis
GlobeNewswire - Thu Jun 02, 12:50AM CDT
Company Announcement

Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen
GlobeNewswire - Mon May 30, 10:00AM CDT
Company Announcement

Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma
GlobeNewswire - Mon May 23, 6:15AM CDT
Company Announcement

Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed May 18, 12:29PM CDT
Company Announcement

Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA
GlobeNewswire - Tue May 17, 3:41PM CDT
Company Announcement
GEN: 2.00 (-0.01)

Genmab Announces Financial Results for the First Quarter of 2016
GlobeNewswire - Tue May 10, 10:15AM CDT
Interim Report for the First Quarter of 2016

Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
GlobeNewswire - Wed Apr 20, 9:53AM CDT
Company Announcement

Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX(r)
GlobeNewswire - Mon Apr 04, 1:10PM CDT
Company Announcement

Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement
GlobeNewswire - Mon Apr 04, 10:48AM CDT
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular features that bind to CD38.

CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory Multiple Myeloma
GlobeNewswire - Fri Apr 01, 10:46AM CDT
-- CHMP issued positive opinion for DARZALEX for relapsed and refractory multiple myeloma

First Phase 3 Trial of Daratumumab in Combination with Standard Therapy in Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint in Planned Interim Analysis
PR Newswire - Wed Mar 30, 11:22AM CDT
Janssen Research & Development, LLC announced today positive results of a pre-planned interim analysis of the Phase 3 MMY3004 (CASTOR) trial evaluating the efficacy and safety of daratumumab, a CD38-directed monoclonal antibody (mAb), in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in patients with relapsed or refractory multiple myeloma. The interim analysis, conducted by an Independent Data Monitoring Committee (IDMC), found that the daratumumab combination treatment regimen improved progression-free survival (PFS) compared with bortezomib and dexamethasone alone, achieving the primary study endpoint (p < 0.0001). Based on the recommendation of the IDMC, the study will be stopped early. Study patients originally assigned to the standard treatment group (bortezomib plus dexamethasone) will be offered the option of receiving daratumumab following confirmed disease progression. All patients continue to be followed for long-term safety and overall survival.

Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Wed Mar 30, 11:19AM CDT
Company Announcement

J&J, Roche Tie Up to Study Dual Immunotherapy Combination
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:40PM CDT
Johnson & Johnson (JNJ) inks a clinical trial deal with Roche (RHHBY) to assess dual monoclonal antibody combination therapy.
JNJ: 123.22 (-0.55), AMGN: 173.02 (+0.59)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 231

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 211

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 193

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 249

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 432

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

StorageVault Canada Inc. Declares Q4 Dividend for Stakeholders

Updated Category News Views 91

StorageVault Canada Inc. Declares Q4 Dividend Announcement In a recent announcement, StorageVault Canada Inc. (TSX: SVI) revealed a quarterly dividend of $0.002991 per common share. This dividend is set to be distributed on January 15, 2026, to all shareholders listed as of December 31, 2025, coinciding with the ex-dividend date also on December 31. This designation...

Continue Reading
Calm Tuesday for Major Cryptocurrencies: Insights and Updates

Updated Category News Views 165

Market Overview: Cryptocurrencies in Focus On a quieter Tuesday, major cryptocurrencies such as Bitcoin, Ethereum, and XRP are showing a notable degree of stability. Bitcoin is currently trading just below $87,000 as it contends with the influx of new altcoin spot ETFs entering the market. Key Price Movements As investors navigate the changing landscape, here are the...

Continue Reading
Current Legal Challenge for Sun Communities, Inc. Investors

Updated Category News Views 286

Understanding the Sun Communities, Inc. Class Action Recently, a significant alert regarding Sun Communities, Inc. has been brought to attention for its stockholders. A class action has been initiated against the company due to allegations of misleading investors about possible conflicts of interest. Sun Communities, Inc. (SUI), primarily recognized for its investments in...

Continue Reading
Seeking Justice: BHC Sierra Vista Hospital Faces Allegations

Updated Category News Views 368

Labor Law Violation Allegations Against BHC Sierra Vista Hospital BHC Sierra Vista Hospital, Inc. is currently facing serious allegations for failing to provide its employees with legally mandated meal and rest breaks during their shifts. This alleged neglect not only goes against the California Labor Code but also contributes to the unfortunate situation where employees...

Continue Reading
ZKH Group Limited Reports Q3 2025 Financial Performance Insights

Updated Category News Views 183

Overview of ZKH Group Limited's Financial Results ZKH Group Limited (NYSE: ZKH), a premier platform for maintenance, repair, and operations (MRO) procurement services, has announced its unaudited financial results for the third quarter of 2025. The company has shown resilience and adaptability amidst a challenging economic landscape, with significant operational...

Continue Reading